Celldex refutes false report; barzolvolimab PN study continues, Phase 2 subQ planned

Celldex Therapeutics, Inc.

Inaccurate report at AAD Annual Meeting stated Celldex terminated Phase 1b barzolvolimab study in prurigo nodularis due to SAE.
Celldex clarifies study not terminated; DRC unanimously recommended program proceed despite anaphylactic SAE in complicated patient.
Enrollment closed at 24 patients due to IV administration challenges; blinded study continues with data expected Q4 2023.
Celldex plans Phase 2 subcutaneous study in PN in late 2023 or early 2024.
No safety events reported that would meaningfully impact the barzolvolimab development program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.